Cancers (Mar 2022)

High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand

  • Nicola Zambrano,
  • Guendalina Froechlich,
  • Dejan Lazarevic,
  • Margherita Passariello,
  • Alfredo Nicosia,
  • Claudia De Lorenzo,
  • Marco J. Morelli,
  • Emanuele Sasso

DOI
https://doi.org/10.3390/cancers14051325
Journal volume & issue
Vol. 14, no. 5
p. 1325

Abstract

Read online

Monoclonal antibodies are among the most powerful therapeutics in modern medicine. Since the approval of the first therapeutic antibody in 1986, monoclonal antibodies keep holding great expectations for application in a range of clinical indications, highlighting the need to provide timely and sustainable access to powerful screening options. However, their application in the past has been limited by time-consuming and expensive steps of discovery and production. The screening of antibody repertoires is a laborious step; however, the implementation of next-generation sequencing-guided screening of single-chain antibody fragments has now largely overcome this issue. This review provides a detailed overview of the current strategies for the identification of monoclonal antibodies from phage display-based libraries. We also discuss the challenges and the possible solutions to improve the limiting selection and screening steps, in order to keep pace with the increasing demand for monoclonal antibodies.

Keywords